Clinical activity after fingolimod cessation: Disease reactivation or rebound? by Frau, J. et al.
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/ene.13694 
This article is protected by copyright. All rights reserved. 
DR. JESSICA  FRAU (Orcid ID : 0000-0001-9068-9144) 
DR. ROBERTA  LANZILLO (Orcid ID : 0000-0001-6388-8180) 
 
Article type      : Original Article 
 
Clinical activity after fingolimod cessation: disease reactivation or 
rebound? 
 
Running title: Clinical activity after fingolimod cessation. 
Frau J1, Sormani MP2, Signori A2, Realmuto S3, Baroncini D4, Annovazzi P4, Signoriello E5, Maniscalco G6, 
La Gioia S7, Cordioli C8, Frigeni B7, Rasia S8, Fenu G1, Grasso R9, Sartori A10, Lanzillo R11, Stromillo ML12, 
Rossi S13, Forci B14, Cocco E1 on behalf of the i-MuST study group 
1. Department of Medical Sciences and Public Health, University of Cagliari, Italy. 2. Department of Health Sciences, Section of Biostatistics, 
University of Genova, Italy. 3. Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Palermo, Italy. 4. 
Multiple Sclerosis Study Centre, AO s.Antonio Abate, Gallarate. 5. Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, 
Second University of Naples, Italy. 6. Neurological Clinic and Multiple Sclerosis Centre  of “AORN A.Cardarelli” , Naples, Italy. 7. USC Neurologia, 
ASST Papa Giovanni XXIII, Bergamo, Italy. 8. Multiple Sclerosis Center, Spedali Civili of Brescia, Presidio di Montichiari, Brescia, Italy. 9. 
Neurologia Universitaria OORR Foggia  10. Clinica Neurologica, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Trieste. 11. Department of 
Neurosciences, Reproductive Sciences and Odontostomatology, Multiple Sclerosis Centre, Federico II University, Naples. 12. Dept. of Medicine, 
Surgery & Neuroscience, University of Siena 13. Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico 
Carlo Besta, Via Giovanni Celoria, 11, 20133 Milano, Italy 14. Azienda Ospedaliero Universitaria Careggi, Dipartimento di Neuroscienze, Area del 
farmaco e Salute del bambino (NEUROFARBA) 
 
 
Corresponding author: 
Prof Maria Pia Sormani 
Department of Health Sciences (DISSAL) 
Via Pastore 1, 16132, 
Genova, Italy 
tel +39-0103538473 
mariapia.sormani@unige.it 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Disclosures. 
J Frau serves on scientific advisory boards for Biogen and Genzyme, has received honoraria 
for speaking from Merck Serono, Genzyme, Biogen and Teva. 
MP Sormani has received consulting fees from Biogen, Novartis, TEVA, Merck Serono, Roche, 
Genzyme, GeNeuro, Medday, Celgene 
A Signori has received Fees from Novartis for teaching courses. 
S Realmuto has received honoraria for consultancy from Merck-Serono and Teva; travel grant 
from Sanofi-genzyme, Novartis and Biogen. 
D Baroncini has received travel grants from Genzyme, Novartis, and Merck for participation at 
national and international congresses; he received personal compensation from Almirall for 
scientific publication and honoraria from Sanofy for participating to advisory board. 
P Annovazzi has received honoraria for lecturing and participation in advisory boards, and/or 
travel expenses for attending congresses and meetings from Merck, Biogen, Teva, Sanofi-
Genzyme, Almirall, Mylan, Roche and Novartis. 
E. Signoriello has received travel funding and speaker honoraria from Biogen, Novartis, Sanofi 
Genzyme, Bayer, Teva. 
G.T. Maniscalco has received travel assistance and/or honoraria from, and provided advice to 
Biogen Idec, Novartis, Genzyme, Sanofi-Aventis and Merck-Serono. 
S La Gioia has received grants from Novartis 
C Cordioli has received consulting fees for speaking from Novartis, Merk Serono, TEVA, 
Biogen.  
G Fenu has received honoraria for consultancy from Novartis and Biogen, and for speaking 
from Merck Serono and Teva. 
 
A Sartori has received funding for travel and/or speaker honoraria from Teva, Novartis, 
Almirall, Genzyme. 
 
R Lanzillo has received personal fees for public speaking or consultancy from Merck, Novartis, 
Biogen, Genzyme, Teva and Almirall. 
 
S Rossi acted as an Advisory Board member of Biogen Idec, Bayer Schering, Merck Serono, 
Teva, Novartis, Mylan and Genzyme, and received funding for traveling and honoraria for 
speaking or writing or consultancy from Biogen Idec, Merck Serono, Teva, Novartis, Bayer 
Schering, Genzyme, Almirall. She received support for research project by Teva, Merck Serono 
and Bayer Schering. She is involved as principal investigator in clinical trials for Teva, 
Novartis, Biogen and Roche. 
B Forci has received travel grants from Novartis, Biogen and Genzyme. 
E Cocco has received honoraria for consultancy or speaking from Bayer, Biogen, Novartis, 
Sanofi, Genzyme, Merck and Teva. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
S Rasia, R Grasso, ML Stromillo, B Frigeni have nothing to disclose about this work. 
Funding. 
The study did not receive any funding. 
 
Keywords: Multiple sclerosis; fingolimod; rebound; reactivation 
 
Abstract 
Objective. There is debate as to whether the apparent rebound after fingolimod 
discontinuation is related to the discontinuation itself, or if it is due to the natural course of 
highly active multiple sclerosis (MS). 
We aimed to survey the prevalence of severe reactivation and rebound after discontinuation 
of fingolimod in a cohort of Italian patients with MS.  
Methods. Patients with relapsing-remitting MS (RRMS) who were treated with fingolimod for 
at least 6 months and who stopped treatment for reasons that were unrelated to inefficacy 
were included in the analysis.  
Results. A total of 100 patients who had discontinued fingolimod were included in the study. 
Fourteen patients (14%) had a relapse within 3 months after fingolimod discontinuation, and 
an additional 12 (12%) had a relapse within 6 months. According to this study’s criteria, 10 
patients (10%) had a severe reactivation. Among these patients, 5 (5%) had a reactivation 
that was considered to be a rebound. 
Conclusions 
The present study showed that more than 26% of patients are at risk of having a relapse 
within 6 months after fingolimod discontinuation. Nevertheless, the risk of severe 
reactivations and rebound that we found is lower than that which has been previously 
described. 
 
Introduction 
Fingolimod was the first oral treatment to become available for multiple sclerosis (MS). In 
Europe, its use is indicated for aggressive forms of relapsing-remitting (RR) MS. Data from 
clinical trials showed that annualized relapse rates (ARR) were more than 50% lower in 
subjects taking oral fingolimod as compared to subjects taking placebo [1,2]. Since 2012, 
several reports have described a “rebound syndrome” after fingolimod discontinuation [3,14]. 
There is not a shared definition of “clinical rebound syndrome”; the most widely used 
definition is “a disease reactivation which surpasses the pretreatment activity level,” 
especially with regard to ARR [15,16]. The concept of “rebound” after discontinuation of 
treatment was first proposed for natalizumab, a monoclonal antibody approved in 2006 to 
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treat the aggressive course of MS [17]. To date, only one study has explored the frequency of 
this phenomenon in patients with MS who discontinued fingolimod use. In this study, a 
clinical rebound syndrome was detected in 5 out of 46 subjects of a small cohort of patients 
who were referred to a single site (10.9%) [18]. However, a recent post-hoc analysis of the 
Phase III, placebo-controlled FREEDOMS and FREEDOMS II trials did not find any difference 
in the emergence of clinical rebound between patients treated with fingolimod and placebo 
[16]. To note, the minimum time of exposure of the patients evaluated in that post-hoc 
analysis was 3 months, and a so short exposure may less likely to cause a rebound. In 
addition, the FREEDOM trials collected MRI data post fingolimod discontinuation only for 3 
months, and the subjects included in the rebound analysis are a small fraction of those 
enrolled.  
While there is agreement in the literature that there is a high risk of rebound after 
natalizumab discontinuation [17], the concept of rebound after fingolimod cessation is less 
well defined. 
The aim of this multicenter study was to evaluate the presence of clinical rebound syndrome 
after fingolimod discontinuation in a cohort of Italian patients with MS. 
 
Materials and methods. 
The patients who were enrolled in this study were recruited from 14 Italian MS centers 
between March and October 2017, after signed informed consent. The study was approved by 
the local ethics committees. The inclusion criteria were as follows: diagnosis of RRMS 
according to the McDonald criteria, previous treatment with fingolimod for at least 6 
consecutive months over the person’s lifetime, an absence of relapses in the last 6 months of 
treatment with fingolimod, and suspension of fingolimod due to reasons other than inefficacy 
(i.e., desire to become pregnant, side effects, self-discontinuation). In following the Italian 
Agency of Drug (AIFA) dispositions, all subjects started fingolimod due to aggressive disease 
from the onset (naïve patients), inefficacy of first-line treatments (switching patients), or a 
high risk of progressive multifocal leukoencephalopathy (PML) during natalizumab therapy. 
At each center from which patients were recruited, a neurologist with expertise in MS 
diagnosis and treatment collected the following demographic and clinical information from 
the patients’ data records: gender; year of birth; age at onset; comorbidities; the last disease 
modifying drug (DMD) before fingolimod and the first DMD after its discontinuation; reason 
for suspension of fingolimod; ARR before, during, and after fingolimod; and Expanded 
Disability Status Scale (EDSS) score at the time that fingolimod was started and stopped, as 
well as during the post-suspension relapses.  
 
A severe reactivation was defined as a relapse with an associated EDSS increase of at least 2 
points or as 2 or more relapses in the 6 months following fingolimod discontinuation. A 
rebound was defined when a so high clinically severe reactivation, as previously described, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
was never reported in patient’s lifetime before fingolimod discontinuation. Thus, if the patient 
experienced the same severe disease activity both after fingolimod cessation and before (in 
any period of the course of the disease), that reactivation was not considered a rebound.  
 
Statistical analysis 
Quantitative results are presented as mean and standard deviation (SD) or median with the 
interquartile range (IQR). Absolute counts and percentages are reported for counts and 
binary variables. To evaluate demographic and clinical features as possible prognostic factors 
for severe reactivation after discontinuation of fingolimod, comparisons between patients 
with and without a severe reactivation were made using an independent samples Student’s t 
test (age at first dose of fingolimod), a non-parametric Mann-Whitney U test (disease duration 
at first dose of fingolimod, duration of fingolimod treatment, EDSS score at fingolimod 
discontinuation, and ARR in the year before fingolimod initiation), and a chi-square test 
(gender and comorbidities). A p-value of <0.05 was considered statistically significant. 
Statistical analyses were performed with Stata (v.14; StataCorp) software. 
 
Results 
A total of 100 patients, 80 female (80%) and 20 male (20%), were included in the study. The 
mean age at onset was 27 years (SD: 8.7). At the time that fingolimod was started, the median 
EDSS and the mean duration of the disease were 2 (IQR: 1.5-3.5) and 10.7 (SD: 6.8), 
respectively. The median EDSS at the end of the treatment was 2 (IQR: 1-3.5). The mean 
duration of fingolimod treatment was 1.9 years (SD: 1.5, range: 0.5-5.9). 
The vast majority of patients (70, 69.3%) started fingolimod therapy due to inefficacy of the 
first-line treatment, whereas 26 (25.75%) switched from natalizumab due to the high risk of 
PML and 5 (4.95%) had an aggressive course of the disease and were naïve to DMDs. The 
reasons for discontinuation of fingolimod were side effects or adverse events in 57 patients 
(57%), the desire to become pregnant in 33 patients (33%), and the patient’s choice in 10 
patients (10%). 
After fingolimod, a new DMD was started in 72 patients within a median time of 3 months 
(IQR: 1.1-6.1). Sixty subjects did not experience any relapse after fingolimod discontinuation 
during the whole follow-up. Of them, 40 started a new DMD after a mean time of 5 months 
(IQR: 0.9-4.8). The ARR before, during, and after fingolimod regarding the whole cohort of 
patients is shown in figure 1. 
Forty subjects had a relapse during the follow-up. In particular, 14 out of 100 patients (14%) 
had a relapse within 3 months after fingolimod discontinuation (only 1 started a new therapy 
within 3 months from the time that fingolimod was discontinued), and an additional 12 
patients (12%) had a relapse within 6 months (5 started a new therapy within 6 months from 
the time that fingolimod was discontinued). According to the above-mentioned criteria, 10 
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patients (10%) had a clinically severe reactivation. Among them, 1 had a relapse associated 
with an EDSS increase of 6 points, 2 had a relapse associated with an EDSS increase of 3.5 
points, 2 had a relapse associated with an EDSS increase of 2 points, and 5 had at least 2 
relapses over 6 months. Upon analysis of the patients with severe reactivation, 5 of them (5% 
of the whole cohort) were defined as having had a clinical rebound. The demographic and 
clinical features of patients who experienced severe reactivation and rebound of the disease 
after discontinuation of fingolimod are reported in table 1. 
 
From the analysis of clinical and demographic features, we were not able to detect significant 
prognostic factors for severe reactivation of disease. However, patients with a severe 
reactivation were younger and all were female. The detailed results are presented in table 2. 
The details about EDSS course, new and enhancing lesions on the brain MRI, and features of 
clinical reactivation are reported in the table 3. 
 
Discussion 
We conducted a retrospective, observational, real-life study involving a cohort of MS patients 
who were treated with fingolimod and who discontinued therapy for reasons other than poor 
efficacy. According to AIFA dispositions, when fingolimod was started all of the patients had 
an aggressive disease course, defined either as at least one relapse during interferon beta or 
glatiramer acetate treatment, or at least 2 relapses in the last year if the patient was not 
taking a DMD. Moreover, the patients’ disease was stable during treatment, and the treatment 
was discontinued for side effects, the desire to become pregnant, or reasons other than 
inefficacy. In our cohort, 10% of patients experienced a severe reactivation of MS, and the 
reactivations of half of these patients met the definition of clinical rebound syndrome. As 
proposed in the recent analysis of the FREEDOMS and FREEDOMS II trials [16], patients 
experiencing a severe reactivation after discontinuation of fingolimod may simply have had a 
high level of MS activity, as compared to their pre-fingolimod clinical histories, which would 
be expected as part of the natural, unpredictable course of the disease.  
It is worth noting that some of the clinical case studies that have described a rebound after 
fingolimod discontinuation [6-9,13], including the small cohort that was described by Hatcher 
et al [18], studied patients in which fingolimod was discontinued due to a lack of efficacy. 
Given that these patients did not respond to fingolimod, a reactivation of the disease would be 
expected upon therapy discontinuation. Recently, a high relapse rate and a low EDSS score 
before fingolimod treatment have been hypothesized to be negative prognostic factors for 
severe disease reactivation within the first 3 months after cessation of the therapy [19]. In our 
study, we were not able to identify factors that were strongly associated with severe 
reactivation after discontinuation of fingolimod. It is important to note, however, that all the 
patients with severe reactivation were female and were also younger than the other subjects, 
despite the fact that these differences did not reach statistical significance. This may have 
been due to the low statistical power of these comparisons.  
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Currently, there is no agreement on the pathological explanation for the supposed rebound. It 
is possible that it is related to a rapid lymphocyte reconstitution [18], but such a 
reconstitution has not been observed in all patients with a rebound. A more likely hypothesis 
is that a differential lymphocyte subset repopulation may be driving the rebound syndrome 
[20]. Moreover, it has been shown in the experimental model of MS, that rebound after 
fingolimod discontinuation is preceded by an overexpression of S1P1 in lymphocytes 
entrapped in lymph nodes, and it correlate with their massive egress from lymph nodes and 
with infiltrates in the Central Nervous System [21].  
One important limitation of this study is that rebound was considered only on the basis of 
clinical, but not radiological, features. This is due to the observational and retrospective 
design of this study, in which data collected in clinical practice was analyzed. MRI 
examinations were not homogeneously performed across centers, both in terms of imaging 
protocols and in terms of timing of the scanning, and only a few patients underwent an MRI 
examination within the first 6 months after fingolimod discontinuation. Of note, clinical and 
radiological rebounds were considered as two separate entities in the analysis of the 
FREEDOMS and FREEDOMS II studies [16]. Another limitation, due to the fact that it is a real 
life study, is the lack of lymphocyte subset after fingolimod discontinuation for the vast 
majority of patients. That being said, the cohort of patients included in this study was selected 
from specialized Italian MS centers that belong to the research group iMUST. Given their 
participation in iMUST, these centers share relatively homogeneous rules for MS treatment 
and for strict observation of AIFA dispositions. In accordance with these prescriptive rules, 
only patients who fail a first line treatment, and those with aggressive course of MS from the 
onset of the disease could take fingolimod. Thus, all the patients had an aggressive course 
before the fingolimod initiation. 
In conclusion, the rate of rebound after fingolimod discontinuation was estimated to be 5% in 
this relatively large case series, which is a lower risk than that which was previously 
described in another real-life cohort [18]. These data could have an important impact in the 
physician-patient communication, both when fingolimod is proposed as new therapy, and 
when it has to be stopped due to any kind of reason. Moreover, even if the risk emerged from 
our study is not so high as previously described, it has to be considered every time when 
fingolimod is discontinued. To confirm our results, it could be important to conduct other 
real-life studies analyzing the impact of clinical, and possibly, radiological rebound after 
fingolimod cessation in RR MS patients without disease activity before the discontinuation.  
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Table 1 
Demographic and clinical features of patients who experienced severe reactivation of disease 
after fingolimod discontinuation. 
Pt: patients; IFN: interferon beta; nat: natalizumab; GA: glatiramer acetate; AE: adverse event; 
fingo: fingolimod 
 
 
 
 
 
 
 
 
 
 
Pt Rebound Gender Age at onset
DMD pre 
fingo
Relapses 12 
months 
before fingo
MRI before 
fingo: new 
T2
MRI before 
fingo: Gd+
Comorbidity
Washout 
pre fingo 
(months)
Disease 
duration at 
fingo start 
(years)
EDSS at 
fingo 
start
EDSS at 
fingo 
stop
EDSS 
during 
reactivation
Reason for 
suspension
Lymphocytes 
after 
suspension
Time to 
lymphocytes count 
after suspension 
(months)
DMD 
post 
fingo
Time to 
new drug 
(months)
1 yes Female 20 nat 0 no no none 5 5 1 2 2.5 Pregnancy 1200/ul 2 alem 3.7
2 yes Female 25 nat 1 not available not available stroke 7 14 5.5 5 8.5 Pt decision not available none
3 yes Female 14 nat 0.81 no no none 7 16 3 3 9 Pregnancy 1100/ul 7 DMF 5.9
4 yes Female 21 IFN 1.5 yes yes epilepsy 1 4 1.5 2 4 AE not available nat 8.1
5 yes Female 26 nat 0 no no none 6 12 2 2 3 AE 2140/ul 0 nat 5.0
6 no Female 24 IFN 2 no no headache 2 21 2.5 2.5 3 AE 1160/ul 1 IFN 2.9
7 no Female 25 IFN 1 not available not available none 0 13 1 1 2 Pregnancy not available GA 0.8
8 no Female 28 GA 0.84 no no none 2 13 3.5 4 6 Pt decision 1210/ul 0 terifl 0.6
9 no Female 14 nat 2 yes yes none 6 7 1.5 0 2 AE 1289/ul 3 GA 3.7
10 no Female 20 nat 0 not available not available none 4 6 2 1 4.5 AE 1000/ul 0 ritux 2.3
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Table 2. 
Demographic and clinical features in patients with no severe reactivation, with severe disease 
reactivation, and with rebound. 
 
ARR: annualized relapse rate; EDSS: Expanded Disability Status Scale 
 
 No severe 
reactivation 
(n=90) 
Severe 
reactivation 
(n=10) 
Rebound (n=5) 
Age at first dose of fingolimod, mean 
(SD); range 
38.2 (10.2); 18-
60 
32.9 (8.4); 21-
45 
31.6 (6.9); 25-
39 
Female, n(%) 70 (77.8) 10 (100) 5 (100) 
Disease duration at first dose of 
fingolimod (years), mean (SD); 
median (25th-75th) 
10.6 (7); 8.7 
(5.1-15.2) 
11.3 (5.5); 12.2 
(5.6-14.5) 
10.5 (5.5); 12 
(5.3-14.5) 
Duration of fingolimod treatment 
(months), mean (SD); median (25th-
75th) 
25.5 (13.1); 
25.9 (18-28.9) 
22.6 (17); 18.3 
(10.7-30.1) 
26.5 (13.1); 
18.2 (18-39) 
Comorbidities pre-fingolimod, n(%) 51 (56.7) 6 (60) 2 (40) 
ARR before fingolimod, mean(SD) 0.87 (0.77) 0.92 (0.76) 0.66 (0.65) 
EDSS at fingolimod cessation, median 
(25th-75th percentile) 
2 (1-3.5) 2 (1-3) 2 (2-3) 
 
Table 3 
EDSS course, and MRI and reactivation features in patients who experienced a rebound. 
 
 
Figure 1. 
Representation of the annualized relapse rate (ARR) before, during, and after fingolimod in three 
groups of patients: those without relapses after fingolimod discontinuation, those who experienced 
reactivation, and those who experienced a rebound of the disease. 
 
 
Pt
EDSS before 
fingolimod
EDSS at the 
end of 
fingolimod
EDSS during 
the 
reactivation
MRI new T2 
lesions
MRI Gd+ 
lesions
Type of reactivation within 6 months from 
discontinuation
1 1 2 2.5 yes yes 2 relapses
2 5.5 5 8.5 yes yes 2 relapse and EDSS increase > 2 points
3 3 3 9 yes yes one relapse with EDSS increase > 2 points
4 1.5 2 4 yes yes 2 relapse and EDSS increase > 2 points
5 2 2 3 yes yes 3 relapses
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